Proteome technologies in studying the pathogenesisof psoriasis

Abstract

Psoriasis is one of the most prevalent inflammatory dermatoses. At the same time, its pathogenesis has not been studied
in full. Proteome profiling is currently a promising method to study the biological mechanisms of developing different
diseases. Proteome technologies make it possible to detect changes in the skin protein profile in psoriatic patients and
identify the revealed proteins. The proteins serve as potential targets for drugs or biomarkers for assessing the patients
individual drug response. The article describes the key achievements in the field of studying the pathogenesis of psoriasis
using proteome technologies (two-dimensional electrophoresis and mass spectrometry) set out in the latest literature
sources, and also analyzes the results of the authors studies aimed at detecting proteins being markers of the patients
response to the infliximab therapy.

About the authors

L F Znamenskaya

Email: znaml@cnikvi.ru

L F Znamenskaya

References

  1. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
  2. de Korte J., Sprangers M.A., Mombers F.M. et al. Quality of life in patients with psoriasis: a systematic literature review. J invest Derm Symp Proc 2004; 9: 140-147.
  3. Rapp S.R., Feldman S.R., Exum M.L. et al. Psoriasis causes as much disability as other major medical diseases. J Amer acad Derm 1999; 41: 401-407.
  4. Mrowietz U., Reich K. Psoriasis - new insights into pathogenesis and treatment. Dtsch Arztebl Int 2009; 106: 11-18, quiz 19.
  5. Gaspari A.A. Innate and adaptive immunity and the pathophysiology of psoriasis. J Amer acad Derm 2006; 54: S67-80.
  6. Tschachler E. Psoriasis: the epidermal component. Clin Derm 2007; 25: 589-595.
  7. Dika E., Bardazzi F., Balestri R., Maibach H.I. Environmental factors and psoriasis. Curr Probl Dermatol 2007; 35: 118-135.
  8. Говорун В.М., Арчаков А.И. Протеомные технологии в современной биомедицинской науке. Биохимия 2002; 67: 1341-1359.
  9. Omenn G.S. Strategies for plasma proteomic profiling of cancers. Proteomics 2006; 6: 5662-5673.
  10. Huang C.M., Elmets C.A., van Kampen K.R. et al. Prospective highlights of functional skin proteomics. Mass Spectrom Rev 2005; 24: 647-660.
  11. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-2077.
  12. Zhou G., Li H., DeCamp D. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Molec Cell Proteomics 2002; 1: 117-124.
  13. Lottspeich F. Proteome Analysis: A Pathway to the Functional Analysis of Proteins. Angew Chem Int Ed Engl 1999; 38: 2476-2492.
  14. Poon T.C. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Exp Rev Proteomics 2007; 4: 51-65.
  15. Bonnekoh B., Bockelmann R., Pommer A.J. et al. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi- Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay. Skin Pharmacol Physiol 2007; 20: 96-111.
  16. Cowen E.W., Liu C.W., Steinberg S.M. et al. Differentiation of tumour-stage mycosis fungoides, psoriasis vulgaris and normal controls in a pilot study using serum proteomic analysis. Brit J Derm 2007; 157: 946-953.
  17. Macdonald N., Cumberbatch M., Singh M. et al. Proteomic analysis of suction blister fluid isolated from human skin. Clin exp Dermatol 2006; 31: 445-448.
  18. Plavina T., Hincapie M., Wakshull E. et al. Increased plasma concentrations of cytoskeletal and Ca2+-binding proteins and their peptides in psoriasis patients. Clin Chem 2008; 54: 1805-1814.
  19. Celis J.E., Cruger D., Kiil J. et al. Identification of a group of proteins that are strongly up-regulated in total epidermal keratinocytes from psoriatic skin. FEBS Lett 1990; 262: 159-164.
  20. Celis J.E., Rasmussen H.H., Olsen E. et al. The human keratinocyte two-dimensional gel protein database: update 1993. Electrophoresis 1993; 14: 1091-1198.
  21. Madsen P., Rasmussen H.H., Leffers H. et al. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J invest Derm 1992; 99: 299-305.
  22. Carlen L.M., Sanchez F., Bergman A.C. et al. Proteome analysis of skin distinguishes acute guttate from chronic plaque psoriasis. J invest Derm 2005; 124: 63-69.
  23. Takeda A., Higuchi D., Takahashi T. et al. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J invest Derm 2002; 118: 147-154.
  24. Брускин С.А., Абдеев Р.М., Мошковский С.А. и др. Протеомные исследования псориаза как подход к идентификации потенциальных мишеней фармакотерапии. Клин. дерматол. и венерол. 2009; 1: 28-31.
  25. Bonnekoh B., Pommer A.J., Bockelmann R. et al. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment. Skin Pharmacol Physiol 2007; 20: 237-252.
  26. Zgoda V.G., Moshkovskii S.A., Ponomarenko E.A. et al. Proteomics of mouse liver microsomes: performance of different protein separation workflows for LC-MS/MS. Proteomics 2009; 9: 4102-4105.
  27. Foell D., Wittkowski H., Vogl T. et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
  28. Pouliot P., Plante I., Raquil M.A. et al. Myeloid-related proteins rapidly modulate macrophage nitric oxide production during innate immune response. J Immunol 2008; 181: 3595-3601.
  29. Nukui T., Ehama R., Sakaguchi M. et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem 2008; 104: 453-464.
  30. Park C.C., Kim K.J., Woo S.Y. et al. Comparison of the Expression Profile of JunB, c-Jun, and S100A8 (Calgranulin A) in Psoriasis Vulgaris and Guttate Psoriasis. Ann Derm 2009; 21: 35-38.
  31. Benoit S., Toksoy A., Ahlmann M. et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Brit J Derm 2006; 155: 62-66.
  32. Eaton D.L., Bammler T.K. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci 1999; 49: 156-164.
  33. Savas B., Arslan G., Gelen T. et al. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res 1999; 19: 4413-4420.
  34. Luo L., Wang Y., Feng Q. et al. Recombinant protein glutathione S-transferases P1 attenuates inflammation in mice. Molec Immunol 2009; 46: 848-857.
  35. Zhou J., Wolf C.R., Henderson C.J. et al. Glutathione transferase P1: an endogenous inhibitor of allergic responses in a mouse model of asthma. Am J Respir Crit Care Med 2008; 178: 1202-1210.
  36. Aceto A., Caccuri A.M., Sacchetta P. et al. Dissociation and unfolding of Pi-class glutathione transferase. Evidence for a monomeric inactive intermediate. Biochem J 1992; 285 ( Pt 1): 241-245.
  37. Shuttleworth S.J., Bailey S.G., Townsend P.A. Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases. Curr Drug Targets 2010 Nov; 11(11): 1430-8.
  38. Besgen P., Trommler P., Vollmer S. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. J Immunol 2010; 184: 5392-5402.
  39. Zabalawi M., Bharadwaj M., Horton H. et al. Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? J Lipid Res 2007; 48: 52-65.

Statistics

Views

Abstract: 1004

PDF (Russian): 785

Article Metrics

Metrics Loading ...

Dimensions

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Znamenskaya L.F., Znamenskaya L.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies